Kids Brain Health Network, Mental Health Across Generations: the role of antidepressants in maternal and child wellbeing

Screen Shot 2018-06-14 at 8.58.05 AM

Existing evidence on the impact of antidepressant use during pregnancy on child development is often too mixed to offer women concrete answers about the implications for their children.

This difficult, but urgent area of research has been a long-term research interest for Network Investigator Dr. Tim Oberlander, and the focus of a Brain Canada-KBHN postdoctoral fellowship for Dr. Sarah Hutchison, who presented findings on the effects of SSRIs, on children 12 years following prenatal exposure to the common antidepressant at the Pediatric Academic Societies 2018 Meeting in May.

The KBHN-funded study found the children scored higher than controls on a task that measures thinking and attention skills. The work builds on Oberlander and colleagues’ earlier work following 51 children and their mothers since 26 weeks of pregnancy.

“The impact of prenatal antidepressant exposure is not a simple cause and effect,” says Dr. Oberlander. “When it comes to assessing the long-term impact of SSRI exposure before birth, genes and family-life also play a powerful role in influencing how a child grows and develops.

“At the core of this whole story is mother’s mental health,” adds Dr. Oberlander. “We have to talk about what it is about mother’s mental health during pregnancy that influences not only her health, but the health of her fetus and her child.”

While the full picture of antidepressants’ effect during pregnancy is far from complete, “no treatment is not an option,” observes Dr. Hutchison. “It’s important that women who are pregnant and making decisions about whether to take antidepressants or not have a discussion with their physician or midwife. That’s really the key message.”

“I want to emphasize that this is a big public health issue, and the medication part is a subset of the bigger story about pregnancy-related maternal mood disorders,” adds Dr. Oberlander. “Depression during pregnancy and after is a major public health problem that affects mothers and their children.

“The impact of maternal mental health and related medication treatment during pregnancy go on long after birth,” he adds, “and in that sense, represent an influence of mental health across two generations.”

“Further research is needed to examine whether ‘better’ cognitive skills in children with antidepressant exposure reflect a developmental advantage in some ways but also perhaps a risk in other ways, such as perhaps increased anxiety (Hanley et al, 2015),” reflects Dr. Oberlander. “Our findings when the children were 3 and 6 years of age indicated increased levels of anxiety, though the absence of this at 12 years might indicate that as executive functioning improves, children are able to help calm themselves.

“At this point we are fairly cautious in interpreting these results because data collection is ongoing,” agrees Dr. Hutchison. This is just a preliminary sample that we’ve examined so far,” adding that more research is needed before we can confidently comment on the long term consequences or benefits of this prenatal exposure.

In the end, says Dr. Oberlander, the story of this research is not one of the drugs being good or bad, or depression being good or bad. “This is must be a story of how can we support and optimize children’s developmental and mental health, even under adverse circumstances, regardless of what the particular exposure is. That’s the important thing. At a clinical level as a developmental pediatrician, my focus is really on how does this child think, act, and behave, and how can we support their development in the best ways possible, rather than saying ‘this is a population of kids that got exposed to a drug, we have to treat them in this way.’ It doesn’t work like that. It is not one size fits all.

“I hope that my work will provide a much more nuanced story that tell us about a variety of developmental outcomes and that should help us make much more precise and personal interventions for therapy.”

For more information on the SSRI  study, click here for the press release from PAS.

Retrieved from

Research: Human Drug Addiction Behaviors Tied to Specific Impairments in 6 Brain Networks


Summary: A new study reports impairments in six brain networks are associated with addiction behaviors. The findings may pave the way for developing more targeted treatments for addiction.

Source: Mount Sinai Hospital.

Specific impairments within six large-scale brain networks during drug cue exposure, decision-making, inhibitory control, and social-emotional processing are associated with drug addiction behaviors, according to a systematic review of more than 100 published neuroimaging studies by experts at the Icahn School of Medicine at Mount Sinai and published Wednesday, June 6 in the journal Neuron.

Drug addiction is a disorder that encompasses not only excessive drug-seeking and taking, but also fundamental changes in cognition and emotional processing. It comprises core clinical symptoms and behavioral manifestations including a chronically relapsing cycle of intoxication, bingeing, withdrawal, and craving that propels uncontrollable drug use despite adverse consequences and a reduction in the pleasure derived from the drug. While much of the early research on drug addiction focused on understanding the rewarding properties of the drug, recent research has made it increasingly clear that cognitive and emotional impairments support the initiation, escalation, and maintenance of the cycle of addiction. A better understanding of the underlying impaired neural mechanisms in human drug addiction is critical to paving the way for the development of more targeted, evidence-based treatment interventions and timely prevention approaches.

The Impaired Response Inhibition and Salience Attribution (iRISA) model, first published in 2002 by Rita Goldstein, PhD, Professor of Psychiatry and Neuroscience and Director of the Neuropsychoimaging of Addiction and Related Conditions research program at the Icahn School of Medicine at Mount Sinai, and Nora Volkow, Director of NIDA, proposed that impairments of two broad neuropsychological functions–response inhibition (a cognitive process that permits individuals to inhibit their impulses) and salience attribution (the property of tagging something as valuable or important)–and their underlying neural substrates contribute to the cycle of addiction across a broad range of substances of abuse.

The iRISA model uses multiple neuroimaging modalities including magnetic resonance imaging, electroencephalogram (EEG) and derived event-related potentials, positron emission tomography, and neuropsychological testing to explore the underlying neurobiology of human drug addiction and the shift to excessive salience attributed to the drug and drug-related cues at the expense of other salient reinforcers as associated with impaired self-control (especially in a drug related context) and increased drug taking in drug addicted individuals.

“We conducted the current review to update the iRISA model with the most recent evidence from the neuroimaging literature by systematically reviewing 105 task-related neuroimaging studies published since 2010,” says Dr. Goldstein, last and senior author of the paper. “We found consistent impairments in brain function in six large-scale brain networks during performance of different tasks. While the involvement of these specific brain networks was task-specific, we generally observed that in a drug-related context (e.g., during exposure to drug cues) drug addicted individuals had increased engagement of the brain networks underlying decision making, inhibitory control, and social-emotional processing, but a blunted response during non-drug related tasks, as predicted by the iRISA model.”

Please click to read the full article

Mental Health Commission of Canada: Suicide Prevention Toolkits

MHCCWhat is it  

The Mental Health Commission of Canada (MHCC), in collaboration with the Canadian Association for Suicide Prevention, the Centre for Suicide Prevention, and the Public Health Agency of Canada has developed 2 toolkits to support people who have been impacted by suicide. One toolkit is tailored for people who have attempted suicide , and the other is focused on resources for people who have lost someone to suicide . The MHCC wishes to thank the Advisory Committee comprised of people with lived experience related to suicide for their assistance in making these toolkits possible.

In the summer of 2017, the MHCC conducted an online survey to elicit feedback from people who have been affected by suicide. With over a thousand responses, the survey helped gain a better understanding of what topics, content areas, resources, and information were important to include in the toolkits.


Many respondents indicated a preference for “people-first” language as opposed to “survivorship language”. For this reason, “people-first” language is used in the toolkit. That said, many of the resources linked from the toolkits use “survivorship” language.

Please note that the toolkits are not intended to replace a conversation and are not designed to be an exhaustive list of the wide variety of resources available across Canada for support. If you or someone you know is experiencing distressing thoughts or thoughts of suicide, please contact your local distress centre or Kids Help Phone .

Please click images to download the toolkits.

Screen Shot 2018-06-07 at 9.29.17 AM

Screen Shot 2018-06-07 at 9.29.39 AM


Journal of Fetal Alcohol Spectrum Risk & Prevention


The Journal of Fetal Alcohol Spectrum Risk & Prevention strives to serve as an international resource for scientific publications on the epidemiology, neurobiology, psychology and sociology of fetal alcohol toxicity. A strong emphasis will be placed on prevention and risk reduction. 

Message From The Editor: Tom Leibson, MD

The recent decade has fostered an amazing advancement in addiction research, yet we are still far from understanding the entire spectrum of consequences associated with fetal exposure to addictive substances and how to prevent them from happening. This knowledge gap exists despite global multi-disciplinary research and millions of dollars invested in addiction biochemistry, neurology and psychology. Cognizant of the matter, our new journal is designed to attract and showcase novel data regarding the most common teratogenic drug of abuse – alcohol.

This dedicated publication venue is not meant to replace existing journals but rather allow the community of clinicians and scientists who are interested in the clinical implications of fetal alcohol research findings to prioritize discussions concerning risk stratification and prevention of fetal alcohol harm.

Over the years several key assumptions had been challenged in our field and one that is most fascinating addresses the role of parental contribution to the fetal alcohol spectrum of clinical findings and outcomes. Once attributed solely to the molecular toxicity of alcohol, it is now becoming more evident that FASD has strong associations to parental mental health and the early years exposure to parental behaviours. As the pendulum swings, we may see a gradual shift from defining alcohol as a toxin exclusively to viewing it also as a biomarker of parental distress so profound that its impact crosses from generation to generation.

I congratulate the authors who have joined us for this exciting journey and have contributed their science to the launching issue of the Journal of Fetal Alcohol Syndrome Risk and Prevention. I expect to see an ongoing involvement and interest of the entire medical community in this rapidly growing research area, and most importantly I am sincerely hoping that our joint effort will have a positive impact on the lives of our patients and their families.

For more information on the journal and to sign up for the publishing notification service for this journal, please click Register link. This registration will result in the reader receiving the Table of Contents by email for each new issue of the journal. 

Alberta Abuse Line


If you suspect that an Albertan is being abused or neglected, Alberta has a provincial abuse line. 

Who to call

If you suspect an adult or child is being abused or neglected, help is just a phone call away.

The provincial abuse helpline will connect you to resources, supports, services, and referrals to address your concerns. Callers can remain anonymous.

Call 1-855-4HELPAB (1-855-443-5722)

Hours of operation: 7:30 am to 8 pm, Monday to Friday

Call 911 if someone is in immediate danger.

What to expect

  • Anyone can call the abuse helpline to share concerns about alleged abuse or neglect.
  • Be prepared to provide as much detailed information as you can about the alleged abuse or neglect.
  • If you’re calling with concerns about another person, you don’t have to provide your name and contact information. However, it would be helpful in case there are additional questions.
  • After listening to your concern, your call will be directed to the appropriate service or support.
  • If the person you are concerned about already accesses provincial supports, Community and Social Services will follow up with the individual to offer additional help.

Signs of abuse or neglect

Actions causing discomfort, pain or injury.
Examples include hitting, slapping, pushing or kicking.
Actions or statements causing anguish, fear or diminished self-esteem or dignity.
Examples include threatening, intimidating, harassing or humiliating.
Non-consensual sexual contact, activity or behaviour.
Examples include unwanted or inappropriate touching.
Fraud, trickery or theft involving labour, money or property.
Examples include misusing a person’s funds or assets.
Failure to provide the basic level of care, such as food, clothing, shelter or medical treatment.

Not sure?

If you think someone is being abused or neglected, but you’re not sure, call the abuse helpline to discuss your concerns.

If you have reasonable and probable grounds to believe a child is being harmed or is in danger of being harmed, you have an obligation to report it. 

Alberta Supports Contact Centre

The provincial abuse helpline is operated by the Alberta Supports Contact Centre.

Help is available in more than 100 languages.

Hours of operation: 7:30 am to 8 pm, Monday to Friday

Umbilical Cord Tissue: A Better Way to Test for Prenatal Drug Exposure?


Maureen A. O’Reilly, DNP, NNP-BC

Clinicians are searching for quicker and easier collection methods and more accurate toxicology testing for infants affected by intrauterine substance exposure. Umbilical cord testing offers some striking advantages over the “gold standard” of meconium testing, making the switch to cord testing increasingly attractive.

Pregnancy and Drugs of Abuse

Women in their reproductive years are at high risk for substance use disorder.[1] Unfortunately, many women continue unhealthy and addictive substance use behaviors throughout their pregnancies.[2] In a 2012 national survey,[2]5.9% of pregnant women admitted to illicit drug use, 8.5% drank alcohol, and 15.9% smoked cigarettes.[2] The opioid crisis and increased substance use in pregnancy have triggered a national debate,[3] politicizing both detection and treatment for women and their infants. This mix of politics, money, science, and social opinion pressures healthcare clinicians to constantly re-examine how they detect and treat substance use in pregnancy.

The Impact on Newborns

As many as 400,000-440,000 newborns (10%-11% of all births) are exposed to tobacco, alcohol, or illicit drugs each year.[4] In-utero substance exposure is associated with birth defects, premature delivery, fetal alcohol spectrum disorders, and developmental, behavioral, and cognitive problems in affected children.[5,6]

Neonatal abstinence syndrome is a disorder of central and autonomic nervous and gastrointestinal systems that occurs when intrauterine substance exposure causes the newborn to experience withdrawal after birth.[7] Rapid, accurate newborn toxicology testing is crucial in identifying affected newborns, allowing timely initiation of treatment.

Toxicology Testing Matrices

Meconium toxicology has long been the “gold standard” in detecting newborn exposure to drugs of abuse.[8,9] Meconium samples can be difficult to collect. Fetal stressors during labor or delivery can induce meconium passage,[6] or it can be delayed up to a week, depending on gestational age.[9,10] Alternatively, meconium may be passed but not collected because drug use is neither suspected nor reported until after the sample is no longer available, or a parent may discard a diaper with meconium to avoid illicit drug detection.[10]

Other sample matrices for newborn testing have drawbacks. Cutting a hair sample from a newborn is protested by parents for cosmetic reasons and frequently results in inadequate sample size.[6] Fingernails are small and inadequate for sampling in newborns.[6] Vernix caseosa can be used to detect maternal drug use after 24 weeks of gestation; however, the volume is often inadequate for testing.[6] The window of drug detection in urine is narrow.[9]Newborns often void at the time of birth and may not void again for hours. Furthermore, urine samples can be difficult to obtain in the newborn.[11]

A New Method: Umbilical Cord Toxicology

Dianne Montgomery, a neonatal nurse practitioner, was debating the pros and cons of various tissues and waste products for drug detection in newborns, while also trying to address nursing complaints about sample collection difficulties. She approached the United States Drug Testing Laboratory in 2001 to suggest the umbilical cord as an alternative tissue for infant toxicology.[11]Cord toxicology testing first became available commercially in 2012 and is now offered by several US laboratories.[12]


  1. Forray A. Substance use during pregnancy. F1000Res. 2016;5.
  2. Reitan T. Substance abuse during pregnancy: a 5-year follow-up of mothers and children. Drugs Educ Prev Policy. 2018 Feb 15. [Epub ahead of print]
  3. Bodenner C. How to treat pregnant drug addicts? Your thoughts. Atlantic. May 21, 2015. Source Accessed May 4, 2018.
  4. National Center on Substance Abuse and Child Welfare. Substance-exposed infants: state responses to the problem. January 31, 2018. Source Accessed May 4, 2018.
  5. Interrante JD, Ailes EC, Lind JN, et al; National Birth Defects Prevention Study 1997-2011. Risk comparison for prenatal use of analgesics and selected birth defects, National Birth Defects Prevention Study 1997-2011. Ann Epidemiol. 2017;27:645-653. Abstract
  6. Wabuyele SL, Colby JM, McMillin GA. Detection of drug-exposed newborns. Ther Drug Monit. 2018;40:166-185. Abstract
  7. McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med. 2016;375:2468-2479. Abstract
  8. Colby JM. Comparison of umbilical cord tissue and meconium for the confirmation of in utero drug exposure. Clin Biochem. 2017;50:784-790. Abstract
  9. Concheiro-Guisan A, Concheiro M. Bioanalysis during pregnancy: recent advances and novel sampling strategies. Bioanalysis. 2014;6:3133-3153. Abstract
  10. Montgomery DP, Plate CA, Jones M, et al. Using umbilical cord tissue to detect fetal exposure to illicit drugs: a multicentered study in Utah and New Jersey. J Perinatol. 2008;28:750-753. Abstract
  11. United States Drug Testing Laboratory. CordStat origin with Dianne Montgomery . September 20, 2013. Source Accessed May 4, 2018.
  12. United States Drug Testing Laboratory. Umbilical cord drug tissue testing. Source Accessed May 6, 2018.
  13. Plate C. Identifying alcohol exposed newborns. United States Drug Testing Laboratory. 2012. Source Accessed May 8, 2018.
  14. Marin SJ, Christensen RD, Baer VL, Chantry CJ, McMillin GA. Nicotine and metabolites in paired umbilical cord tissue and meconium specimens. Ther Drug Monit. 2011;33:80-85. Abstract
  15. Wright TE, Milam KA, Rougee L, Tanaka MD, Collier AC. Agreement of umbilical cord drug and cotinine levels with maternal self-report of drug use and smoking during pregnancy. J Perinatol. 2011;31:324-329. Abstract
  16. ARUP Consult®. Newborn drug testing – meconium and umbilical cord tissue. SourceAccessed May 7, 2018.
  17. McMillin GA, Wood KE, Strathmann FG, Krasowski MD. Patterns of drugs and drug metabolites observed in meconium: what do they mean? Ther Drug Monit. 2015;37:568-580. Abstract
  18. ARUP Laboratories. Drug detection panel, umbilical cord tissue, qualitative. SourceAccessed May 8, 2018.
  19. United States Drug Testing Laboratory. Universal umbilical cord collection chain of custody procedure. Source Accessed May 9, 2018.
  20. Hudak ML, Tan RC; COMMITTEE ON DRUGS; COMMITTEE ON FETUS AND NEWBORN; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129:e540-e560. Abstract
  21. American College of Obstetricians and Gynecologists. Opioid use and opioid use disorder in pregnancy. ACOG Committee Opinion 711. August 2017. Source Accessed May 10, 2018.
  22. Palmer KL, Wood KE, Krasowski MD. Evaluating a switch from meconium to umbilical cord tissue for newborn drug testing: a retrospective study at an academic medical center. Clin Biochem. 2017;50:255-261. Abstract
  23. Cotten SW. Drug testing in the neonate. Clin Lab Med. 2012;32:449-466. Abstract


Cite this article: Umbilical Cord Tissue: A Better Way to Test for Prenatal Drug Exposure? – Medscape – Jun 05, 2018.

Retrieved from

Study shows alcohol, tobacco cause more health harm than illegal drugs

A pint of beer and a cigarette

It’s smoking tobacco and drinking alcohol – and not taking illegal drugs – that pose the greatest risks to people’s health, a new international study contends.

Researchers found that alcohol and tobacco use combined cost more than a quarter of a billion disability-adjusted life-years worldwide, while illegal drugs only accounted for tens of millions in comparison. Disability-adjusted life-years is a measurement of overall disease burden, expressed as the number of years lost due to ill health, disability or early death.

High levels of alcohol use

Worldwide, more than one in seven adults smoke tobacco, and one in five reports at least one occasion of heavy drinking in the past month, the review of 2015 data found.


Central, Eastern, and Western Europe have the highest alcohol consumption per person, and the highest rates of heavy consumption among drinkers (50.5%, 48%, and just over 42%, respectively), according to the report, published in the journal Addiction.

In South Africa, 5% of women may be considered to be risky drinkers whereas 28% of men are considered risky drinkers. Risky drinkers are defined as “someone who has drunk five or more standard measurements of alcohol on a single occasion in the past 30 days”.

Those same areas also have the highest rates of tobacco smoking – Eastern Europe 24.2%, Central Europe 23.7%, and Western Europe almost 21%. According to Stats SA, 6% of women smoke tobacco daily, compared to 30% of men in South Africa.


Illicit drug use was far less common worldwide, with fewer than one in 20 people estimated to use marijuana in the past year, with much lower rates of use for amphetamines, opioids, and cocaine, the researchers said.

But the United States and Canada had among the highest rates of dependence on marijuana (749 cases per 100 000 people), opioids (650 cases per 100 000) and cocaine (301 cases per 100 000), according to study co-author Robert West, of University College London and colleagues.

According to UCT researcher, Anine Kriegler, 65% to 70% of drug possession arrests and charges, in South Africa, is for the possession of marijuana. In 2017 a court judge ruled that it would be legal to grow and use marijuana in the privacy of your home. This ruling, however, has yet to be ratified.

In addition, Australia and New Zealand had the highest rate of amphetamine dependence (491.5 per 100 000 people), as well as high rates of dependence on marijuana (694 cases per 100 000 people), opioids (510 per 100 000) and cocaine use (160.5 per 100 000 people). 

Retrieved from

« Older Entries Recent Entries »